<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5407">
  <stage>Registered</stage>
  <submitdate>21/10/2015</submitdate>
  <approvaldate>21/10/2015</approvaldate>
  <nctid>NCT02604433</nctid>
  <trial_identification>
    <studytitle>An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (ÃŸ) Thalassemia</studytitle>
    <scientifictitle>A Phase 3, Double-Blind, Placebo Controlled Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) in Adults With Transfusion Dependent Beta (B)-Thalassemia</scientifictitle>
    <utrn />
    <trialacronym>BELIEVE</trialacronym>
    <secondaryid>ACE-536-B-THAL-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Erythrocyte Transfusion</healthcondition>
    <healthcondition>Beta-Thalassemia</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Luspatercept
Other interventions - Placebo

Experimental: Luspatercept (ACE-536) plus Best Supportive Care (BSC) - Luspatercept, subcutaneous(ly) (SC) once every 21 days

Placebo Comparator: Placebo plus Best Supportive Care (BSC) - normal saline solution subcutaneous(ly) (SC) once every 21 days


Treatment: drugs: Luspatercept
Subjects will start with luspatercept at 1 mg/kg dose level.

Other interventions: Placebo
Placebo, Subcutaneous, every 21 days.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of subjects with hematological improvement from Week 13 to Week 24 compared to 12-week prior to randomization - Hematological improvement(HI) is defined as = 33% reduction from baseline in red blood cell count (RBC) transfusion burden with a reduction of at least 2 units from Week 13 to Week 24 compared to the 12-week. Reported as the Number of RBC units transfused from Week 13 to Week 24, and in the 12 weeks prior to randomization</outcome>
      <timepoint>Up to approximately week 24</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with hematological improvement from Week 37 to Week 48 compared to the 12-week interval prior to randomization - Hematological improvement(HI) is defined as = 33% reduction from baseline in red blood cell count (RBC) transfusion burden with a reduction of at least 2 units from Week 37 to Week 48 compared to the 12-week. Reported as the number of RBC units transfused from Week 37 to Week 48, and in the 12 weeks prior to randomization</outcome>
      <timepoint>Up to approximately 48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with a =50% reduction in red blood cell (RBC) transfusion burden from week 37 to Week 48 - A reduction of =50% in transfusion burden is defined as a reduction of at least 2 units from week 37 to week 48 compared to the 12 week interval prior to randomization for luspatercept plus (best supportive care) BSC Versus placebo plus BSC. Reported as the number of RBC units transfused from Week 37 to Week 48, and in the 12 weeks prior to randomization</outcome>
      <timepoint>Up to approximately 48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with a =50% reduction in red blood cell (RBC) transfusion burden from week 13 to Week 24 - A reduction of =50% in transfusion burden is defined as a reduction of at least 2 units from week 13 to week 24 compared to the 12 week interval prior to randomization for luspatercept plus (best supportive care) BSC Versus placebo plus BSC. Reported as the number of RBC units transfused from Week 37 to Week 48, and in the 12 weeks prior to randomization</outcome>
      <timepoint>Up to approximately 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change from baseline in transfusion burden (RBC units) from Week 13 to Week 24 - Change from baseline as continuous variable</outcome>
      <timepoint>Up to approximately 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change from baseline in liver iron concentration (LIC, mg/g dw) by magnetic resonance imaging (MRI) - Liver iron concentration (LIC) by Magnetic resonance imaging (MRI)</outcome>
      <timepoint>Up to approximately 48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change from baseline in mean daily dose of iron chelation therapy (ICT) - Daily dose of iron chelation therapy (ICT)</outcome>
      <timepoint>Up to approximately 48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change from baseline in serum ferritin - Mean Change in Serum ferritin</outcome>
      <timepoint>Up to approximately 48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change from baseline in total hip and lumbar spine bone mineral density (BMD)by Dual energy x-ray absorptiometry (DXA) - Total hip and lumbar spine bone mineral density (BMD) by Dual energy x-ray absorptiometry (DXA)</outcome>
      <timepoint>Up to approximately 48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change from baseline in myocardial iron by magnetic resonance imaging (MRI) - Myocardial iron by T2 magnetic resonance imaging (MRI)</outcome>
      <timepoint>Up to approximately 48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>TranQOL Quality of Life tool administered within 4 weeks prior to Dose 1 Day 1, and weeks 12, 24, 36 and 48, then every 12 weeks during long term period - Summary statistics for scores from the pre-specified domains will be calculated at each administration time point. Summary statistics will also be calculated for change from baseline in each score at each administration time point.</outcome>
      <timepoint>Up to approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>SF-36 Quality of Life tool administered within 4 weeks prior to Dose 1 Day 1, and weeks 12, 24, 36 and 48, then every 12 weeks during long term treatment period - Summary statistics for the Physical functioning, Role - Physical, General Health, Vitality, Social Functioning domain scores, and the Physical Component summary score, as well as change from baseline in these scores, will be assessed at Week 12, 24, 36 and 48 and then every 12 weeks during the Long-term Treatment Period.</outcome>
      <timepoint>Up to approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The effect of luspatercept on healthcare resource utilization (hospitalizations) versus placebo - hospitalizations in the treatment and placebo arms</outcome>
      <timepoint>Up to approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The effect of luspatercept on healthcare resource utilization (prior concomitant therapies and surgeries) versus placebo - prior concomitant therapies and surgeries in the treatment and placebo arms</outcome>
      <timepoint>Up to approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The effect of luspatercept on healthcare resource utilization (RBC transfusion utilization) versus placebo - RBC transfusion utilization in the treatment and placebo arms</outcome>
      <timepoint>Up to approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects who are transfusion independent for =8 weeks during treatment - Myocardial iron by T2 MRI</outcome>
      <timepoint>Up to approximately 48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of reduction in transfusion burden - The duration of the first response will be calculated for each subject who achieves a response</outcome>
      <timepoint>Up to approximately 48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of transfusion independence - Transfusion independence is defined as absence of any transfusion during any consecutive rolling 8-week time interval within the treatment period, ie, Days 1 to 56, Days 2 to 57 and so on</outcome>
      <timepoint>Up to approximately 48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to erythroid response - Erythroid response is defined as = 33% reduction from baseline in transfusion burden (units RBCs / time) with a reduction of at least 2 units. The analysis of time to response will be based on the data collected during the double-blind phase.</outcome>
      <timepoint>Up to approximately 48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Post-baseline transfusion events frequency versus placebo - Annualized mean change from baseline number of transfusion events will be summarized by treatment groups</outcome>
      <timepoint>Up to approximately 48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic - AUC - Area under the plasma concentration-time curve</outcome>
      <timepoint>up to 9 weeks post last dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic - Cmax - Maximum observed concentration in plasma</outcome>
      <timepoint>up to 9 weeks post last dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse Events (AEs) - Number of participants with adverse events</outcome>
      <timepoint>Up to approximately 3.5 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subjects must satisfy the following criteria to be enrolled in the study:

               1. Male or female, = 18 years of age at the time of signing the informed consent
                  document (ICF).

               2. Subject must understand and voluntarily sign an Inform Consent Form prior to any
                  study-related assessments/procedures being conducted.

               3. Subject is willing and able to adhere to the study visit schedule and other
                  protocol requirements.

               4. Documented diagnosis of ÃŸ-thalassemia or Hemoglobin E/ÃŸ-thalassemia.

               5. Regularly transfused, defined as: 6-20 Red Blood Cell (RBC) units in the 24 weeks
                  prior to randomization and no transfusion-free period for = 35 days during that
                  period.

               6. Performance status: Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.

               7. A female of childbearing potential (FCBP) for this study is defined as a female
                  who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy
                  or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea
                  following cancer therapy does not rule out childbearing potential) for at least
                  24 consecutive months (ie, has had menses at any time in the preceding 24
                  consecutive months). FCBP participating in the study must:

          -  Have two negative pregnancy tests as verified by the Investigator prior to starting
             study therapy. She must agree to ongoing pregnancy testing during the course of the
             study, and after end of study treatment. This applies even if the subject practices
             true abstinence from heterosexual contact.

          -  Either commit to true abstinence from heterosexual contact (which must be reviewed on
             a monthly basis and source documented) or agree to use, and be able to comply with,
             effective contraception without interruption, 28 days prior to starting
             investigational product, during the study therapy (including dose interruptions), and
             for 12 weeks (approximately five times the mean terminal half-life of luspatercept
             based on multiple-dose Pharmacokinetic PK) data) after discontinuation of study
             therapy.

             8. Male subjects must:

          -  Practice true abstinence or agree to use a condom during sexual contact with a
             pregnant female or a female of childbearing potential while participating in the
             study, during dose interruptions and for at least 12 weeks (approximately five times
             the mean terminal half-life of luspatercept based on multiple-dose PK data) following
             investigational product discontinuation, even if he has undergone a successful
             vasectomy.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>- The presence of any of the following will exclude a subject from enrollment:

          1. Any significant medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from participating in the study.

          2. Any condition including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if he/she were to participate in the study.

          3. Any condition that confounds the ability to interpret data from the study.

          4. A diagnosis of Hemoglobin S/ÃŸ-thalassemia or alpha (a)-thalassemia (eg, Hemoglobin H);
             ÃŸ-thalassemia combined with a-thalassemia is allowed.

          5. Evidence of active hepatitis C (HCV) infection, or active infectious hepatitis B, or
             known positive human immunodeficiency virus (HIV).

          6. Deep Vein Thrombosis (DVT) or stroke requiring medical intervention = 24 weeks prior
             to randomization.

          7. Chronic anticoagulant therapy = 28 days prior to randomization, Low Molecular Weight
             (LMW) heparin for Sinus venous Thrombosis (SVT) and chronic aspirin are allowed.

          8. Platelet count &gt; 1000 x 109/L

          9. Insulin-dependent diabetes, ie, chronic treatment with insulin.

         10. Treatment with another investigational drug or device = 28 days prior to
             randomization.

         11. Prior exposure to sotatercept (ACE-011) or luspatercept (ACE-536).

         12. Use of an erythropoiesis-stimulating agent (ESA) = 24 weeks prior to randomization.

         13. Iron chelation therapy, if initiated = 24 weeks prior to randomization (allowed if
             initiated &gt; 24 weeks before or during treatment).

         14. Hydroxyurea treatment = 24 weeks prior to randomization.

         15. Pregnant or lactating females.

         16. Uncontrolled hypertension. Controlled hypertension for this protocol is considered =
             Grade 1 according to NCI Common Terminology Criteria for Adverse Events (CTCAE)
             version 4.0 (current active minor version).

         17. Major organ damage, including:

               -  Liver disease with alanine aminotransferase (ALT) &gt; 3 x the upper limit of normal
                  (ULN) or histopathological evidence of liver cirrhosis/fibrosis on liver biopsy;

               -  Heart disease, heart failure as classified by the New York Heart Association
                  (NYHA) classification 3 or higher, or significant arrhythmia requiring treatment,
                  or recent myocardial infarction within 6 months of randomization.

               -  Lung disease, including pulmonary fibrosis or pulmonary hypertension which are
                  clinically significant.

               -  Creatinine clearance &lt; 60 mL/min (per Cockroff-Gault method).

         18. Proteinuria = Grade 3 according to NCI CTCAE version 4.0 (current active minor
             version).

         19. Adrenal insufficiency.

         20. Major surgery = 12 weeks prior to randomization (subjects must have completely
             recovered from any previous surgery prior to randomization).

         21. History of severe allergic or anaphylactic reactions or hypersensitivity to
             recombinant proteins or excipients in the investigational product (see Investigator
             Brochure).

         22. Cytotoxic agents, immunosuppressants = 28 days prior to randomization.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>2/05/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>335</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>30/04/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Prince of Wales Hospital - Randwick</hospital>
    <hospital>Mater Adult Hospital - South Brisbane</hospital>
    <hospital>Royal Adelaide Hospital Institute of Medical and Veterinary Science - Adelaide</hospital>
    <hospital>Monash Medical Centre - Clayton</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <postcode>2031 - Randwick</postcode>
    <postcode>4101 - South Brisbane</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>6009 - Nedlands</postcode>
    <postcode>2050 - Camperdown</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Plovdiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Varna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Creteil</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille Cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Ampelokipi - Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Rio Patras</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Thessaloniki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Beer Sheva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>HaÃ¯fa (Afula)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Nahariya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Petah Tikva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Brindisi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Cagliari</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Ferrara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Genoa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Naples</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Napoli</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Orbassano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Palermo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Verona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lebanon</country>
      <state>Beirut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Johor</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kedah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Perak</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Sabah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Sarawak</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Wilayah Persekutuan Kuala Lumpur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Georgetown</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Changhua City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei, Zhongzheng Dist.</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Chiang Mai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Tunisia</country>
      <state>Sousse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Tunisia</country>
      <state>Tunis</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Adana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Ankara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Antalya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Izmir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Mersin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London Bloomsbury</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Celgene</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Acceleron Pharma, Inc.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study to
      determine the efficacy and safety of luspatercept (ACE-536) plus Best supportive care (BSC)
      versus placebo plus BSC in adults who require regular red blood cell transfusion due to
      (ÃŸ)-thalassemia.

      The study is divided into the Screening/Run-in Period, double-blind Treatment Period,
      double-blind Long-term Treatment Period, and Post-treatment Follow-up Period.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02604433</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Abderrahmane Laadem, MD</name>
      <address>Celgene Corporation</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>